PSI-7977, an isomer of PSI-7851

Presentations

Selection and Characterization of Hepatitis C Virus Replicons Using Combination of NS3 Protease and NS5B Non-nucleoside Inhibitors or Combination of NS5B Nucleotide Inhibitors
A. Lam et al
International HIV & Hepatitis Virus Drug Resistance Workshop and Curative Strategies,
Dubrovnik, Croatia
June 8-12, 2010

Potent Antiviral Activity Observed with PSI-7851, a Novel Nucleotide Polymerase Inhibitor for HCV, Following Multiple Ascending Oral Doses for 3 Days in Patients with Chronic HCV Infection Background MAD Results Conclusions
E. Lawitz et al
HepDart 2009
Kohala Coast, HI
Dec 6 - 10, 2009

Mechanism of PSI-7851 Activation
E Murakami et al
HepDart 2009
Kohala Coast, HI
Dec 6 - 10, 2009

Antiviral Activity, Pharmacokinetics, Safety, and Tolerability of PSI-7851, a Novel Nucleotide Polymerase Inhibitor for HCV, Following Single and 3 Day Multiple Ascending Oral Doses in Healthy Volunteers and Patients with Chronic HCV Infection.
M. Rodriguez-Torres; et al
60th Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA
Oct 30-Nov 3, 2009

Preclinical
PSI-7851: A Novel Liver-Targeting Nucleotide Prodrug for the Treatment of Hepatitis C
P. Furman et al.
The 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
San Francisco, California, USA
Oct 31-Nov 4, 2008

b-D-2'-Deoxy-2'-fluoro-2'-C-methyluridine Phosphoramidates are Potent and Selective Inhibitors of HCV RNA Replication
Furman P.A., Bao D., Chang W., Du J., Micolochick Steuer H., Nagaratham D., Niu C., Rachakonda S., Ross B.S., Symonds W.T., Wang P., Otto M. J., and Sofia M.J.
15th International Symposium on Hepatitis C Virus & Related Viruses
San Antonio, TX
Oct 5-9, 2008